Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

202514 citationsJournal Article

Authors

Vlado Perkovic · UNSW Sydney

Hernán Trimarchi · Hospital Británico

Vladimı́r Tesař · Charles University

Richard Lafayette · Stanford Medicine

Muh Geot Wong · Concord Repatriation General Hospital

Jonathan Barratt · University of Leicester

Yusuke Suzuki ·

Abstract

Sibeprenlimab resulted in a significant reduction in proteinuria as compared with placebo in patients with IgA nephropathy. (Funded by Otsuka Pharmaceutical Development and Commercialization. VISIONARY ClinicalTrials.gov number, NCT05248646.).

Topics & Keywords

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Natural Compounds in Disease Treatment

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 7, pp. 635-646

DOI: 10.1056/nejmoa2512133

Field-Weighted Citation Impact: 19.45

Command Palette

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Authors

Abstract

Topics & Keywords

Publication Details